Is CLBT a Buy or a Sell? The Bull and Bear Case (2026)

Last updated July 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Cellebrite DI (CLBT) rests on ARR compounding on the subscription shift: Cellebrite finished Q1 2026 with ~$493 million of ARR, up ~21%, and guided Q2 ARR to ~$510 million to ~$513 million with net new ARR of ~$17 million to ~$20 million. The bear case rests on revenue depends on government budgets, so procurement freezes, continuing resolutions and election-cycle delays can push deals across quarters with no change in demand. Analysts covering it publish targets from $15.00 to $28.00 against a $16.01 price, so even the professionals disagree by 61% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

Cellebrite DI Ltd. sells the digital-intelligence toolchain used in criminal investigations. Its access products (the Inseyets line, successor to the UFED hardware kits) unlock and extract data from mobile devices, Guardian handles cloud-based evidence review and sharing across agencies, Pathfinder and the newer AI products correlate evidence across seized devices, and Endpoint Inspector covers computers and corporate endpoints. Customers are police forces, national security agencies, prosecutors and, increasingly, corporate investigations and incident-response teams. The company is headquartered in Petah Tikva, Israel, listed on Nasdaq after a 2021 SPAC merger, and files as a foreign private issuer on Form 20-F. In late 2025 it closed the ~$170 million acquisition of Corellium, whose virtualized ARM device platform is used for mobile app security research, and paired that deal with a restructuring. The investment picture is a subscription software story wearing a government-contracting jacket. Annual recurring revenue reached ~$493 million in Q1 2026, up ~21% year over year, on ~$128 million of quarterly revenue (~$118 million of it subscription) at an ~86% gross margin, with ~$31 million of adjusted EBITDA and a trailing free cash flow margin near ~32%. The balance sheet held ~$535 million in cash and investments with no meaningful debt, so at a ~$3.9 billion market value the enterprise trades near ~7x trailing revenue. What that multiple pays for is renewal-heavy demand from agencies that rarely switch vendors; what it exposes is lumpy public-sector purchasing, an ongoing arms race against Apple and Google device security, and the reputational risk of tools sold to states that misuse them.

The bull case: what would have to be true for $28.00

The most optimistic published target on CLBT is $28.00, +74.9% from the $16.01 price as of August 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. ARR compounding on the subscription shift

Cellebrite finished Q1 2026 with ~$493 million of ARR, up ~21%, and guided Q2 ARR to ~$510 million to ~$513 million with net new ARR of ~$17 million to ~$20 million. Subscription revenue of ~$118 million was ~92% of the quarter's total, a long way from the perpetual-license hardware model the company started with. Retention among police and federal agencies is the mechanism: once an evidence workflow is certified for court use, agencies renew rather than retrain.

2. AI products and the Corellium platform

Genesis, the AI investigation assistant launched in early 2026, drew more than ~500 registered users across 15-plus countries in its first weeks, and management is positioning AI-driven review as the way to cut case backlogs rather than as a new SKU. Corellium's virtualized iOS and Android environments add device research capability that feeds the access roadmap and opens an enterprise app-security buyer outside law enforcement. Cellebrite has also extended into drone and vehicle forensics.

3. U.S. federal recovery and FedRAMP High

The federal business slumped during 2025 budget disruption and is rebounding, with management citing a ~35% year-over-year increase in the federal pipeline. FedRAMP High authorization for the cloud products removes the procurement blocker that kept agencies on premises-only deployments. Federal deals are larger and stickier than local-agency purchases, so the mix shift matters more than the headcount of customers.

4. Cash generation and a net-cash balance sheet

Q1 2026 produced ~$31 million of adjusted EBITDA on ~86% gross margin, with trailing free cash flow margin around ~32% and ~$535 million of cash and investments against no meaningful debt. That funds acquisitions like Corellium without dilution or leverage. Operating margin still sits below what an 86%-gross-margin software company at this scale would typically show, which is the specific line investors watch each quarter.

The bear case: what would have to be true for $15.00

The most pessimistic published target is $15.00, -6.3% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Cellebrite DI is worth if the risks below bite instead of the drivers above.

Revenue depends on government budgets, so procurement freezes, continuing resolutions and election-cycle delays can push deals across quarters with no change in demand. Access capability is a moving target: every iOS and Android hardening release can strip a supported extraction method, and Cellebrite must keep re-earning it, which is why its spring 2026 update advertising iPhone 17 and iOS 26 support was itself news. The reputational exposure is real and recurring, from Amnesty International's 2024 report on Cellebrite tools used against Serbian activists (after which the company stopped selling there) to political scrutiny of its expanded U.S. immigration-enforcement contracts. Competition is well capitalized, with Magnet Forensics and GrayKey combined under private ownership. As an Israel-domiciled foreign private issuer, Cellebrite reports on a 20-F with semiannual rather than quarterly filing obligations, carries regional geopolitical risk, and its GAAP results swing on warrant revaluation and share-based compensation.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding CLBT already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on CLBT

7 analysts cover CLBT, with an average target of $21.29 (+33.0% against $16.01) and a split of 7 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the CLBT forecast and price target page.

How is CLBT valued? (as of August 2026)

Price

$16.01

Market cap

$3.99B

P/E (TTM)

57.18

Forward P/E

24.22

Price / book

7.73

Beta

1.18

52-week range

$11.02 to $19.98

Snapshot for CLBT as of August 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$496 million
ARR (Q1 2026): ~$493 million, up ~21% year over year
Q1 2026 revenue and adjusted EBITDA: ~$128 million revenue, ~$31 million adjusted EBITDA, ~86% gross margin
FY2026 revenue guidance: ~$565 million to ~$571 million
Market capitalization: ~$3.9 billion (~$16 per share, mid-July 2026)
Cash and investments: ~$535 million, no meaningful debt, so roughly ~7x trailing revenue on enterprise value

Q1 2026, reported May 14, met or beat the high end of guidance on both ARR and revenue, and full-year guidance was reaffirmed rather than raised. GAAP net income was ~$30.6 million (~$0.12 diluted), though GAAP figures move with warrant and stock-compensation accounting, so the company steers on ARR and adjusted EBITDA. Second-quarter 2026 results are scheduled for August 13, 2026, and the number under the most scrutiny is net new ARR, which the guidance implies grows about ~50% sequentially at the midpoint.

How do you decide if CLBT is a buy?

Rather than asking whether CLBT is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold CLBT indirectly through an index or sector ETF before adding more.

What would change your mind on CLBT

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: ARR compounding on the subscription shift stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: revenue depends on government budgets, so procurement freezes, continuing resolutions and election-cycle delays can push deals across quarters with no change in demand fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the CLBT stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CLBT against your real portfolio and see your actual exposure before deciding.

Investing in Cellebrite DI with AI

Connect the broker you already use and ask Walnut's AI how CLBT fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

See how it fits your portfolio

FAQ

Is CLBT a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on ARR compounding on the subscription shift, with revenue (ttm) at ~$496 million. The bear case rests on revenue depends on government budgets, so procurement freezes, continuing resolutions and election-cycle delays can push deals across quarters with no change in demand. Analysts covering it are spread from $15.00 to $28.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell CLBT?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Revenue depends on government budgets, so procurement freezes, continuing resolutions and election-cycle delays can push deals across quarters with no change in demand. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $15.00, -6.3% from the $16.01 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for CLBT?

ARR compounding on the subscription shift. Cellebrite finished Q1 2026 with ~$493 million of ARR, up ~21%, and guided Q2 ARR to ~$510 million to ~$513 million with net new ARR of ~$17 million to ~$20 million. The most optimistic analyst target on CLBT is $28.00, +74.9% from the $16.01 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for CLBT?

What does Cellebrite DI do?

Israeli digital-forensics software company whose tools extract and analyse evidence from phones and computers for law enforcement and enterprises.

What would have to change for CLBT to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (ARR compounding on the subscription shift) stalling in the reported numbers rather than in the narrative, the risk above (revenue depends on government budgets, so procurement freezes, continuing resolutions and election-cycle delays can push deals across quarters with no change in demand) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What is CLBT and what does the company do?

CLBT is the Nasdaq ticker for Cellebrite DI Ltd., an Israeli company that makes digital investigation software. Its tools extract data from locked phones and computers, organize that evidence in the cloud for prosecutors and investigators, and increasingly use AI to correlate findings across devices in a case.

Which exchange is CLBT listed on?

Cellebrite trades on the Nasdaq as CLBT, having gone public through a SPAC merger in 2021. Because it is headquartered in Petah Tikva, Israel, it reports as a foreign private issuer and files an annual report on Form 20-F instead of a 10-K, though it still publishes quarterly results and holds quarterly calls.

How does Cellebrite make money?

Almost entirely through multi-year software subscriptions rather than one-time hardware sales: subscription revenue was ~$118 million of the ~$128 million reported in Q1 2026. That is why the company reports annual recurring revenue, which reached ~$493 million in Q1 2026, as its headline metric, since ARR signals contracted future revenue before it is recognized.

Walnut is informational, not investment advice, and gives no verdict on CLBT. Analyst targets referenced here come from a August 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.